Alithea Genomics key facts
as of Oct 2026- Developer of cost-efficient transcriptomics designed to perform biomedical discoveries.
- Alithea Genomics is valued at approximately $66.4M as of Oct 2026 (last reported valuation).
- It has raised $9.1M; the latest was Seed Round ($8.9M) in Mar 2026.
- Notable investors include Venture Kick, Ecole Polytechnique Federale de Lausanne, Kickfund, Zürcher Kantonalbank, Biopole — 8 tracked in total.
- Status: Privately Held (backing).
Alithea Genomics's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch Alithea Genomics: the Monday email on marks, rounds and moves
Alithea Genomics funding rounds
No funding rounds for Alithea Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Alithea Genomics valuation
Alithea Genomics's last reported valuation was $66.4 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
Alithea Genomics investors
8 investors are on record for Alithea Genomics, including Venture Kick, Ecole Polytechnique Federale de Lausanne, Kickfund and Zürcher Kantonalbank.
About Alithea Genomics
Developer of cost-efficient transcriptomics designed to perform biomedical discoveries. The company's transcriptomics uses its proprietary technology to optimize the operational costs of Ribonucleic acid sequencing and significantly increase the throughput of analyzed samples, enabling pharmaceutical companies to perform biomedical research.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2020
- Employees
- 34
- Website
- alitheagenomics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.